HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
Top Cited Papers
Open Access
- 20 July 2014
- journal article
- research article
- Published by Springer Science and Business Media LLC in Gastric Cancer
- Vol. 18 (3), 476-484
- https://doi.org/10.1007/s10120-014-0402-y
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- HER2 testing in gastric cancer: a practical approachLaboratory Investigation, 2012
- Association of HER2/ErbB2 Expression and Gene Amplification with Pathologic Features and Prognosis in Esophageal AdenocarcinomasClinical Cancer Research, 2012
- Molecular Classification of Gastric Cancer: A New ParadigmClinical Cancer Research, 2011
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testingVirchows Archiv, 2010
- Gastric cancerCritical Reviews in Oncology/Hematology, 2009
- HER2 in gastric cancer: a new prognostic factor and a novel therapeutic targetAnnals Of Oncology, 2008
- Capecitabine and Oxaliplatin for Advanced Esophagogastric CancerNew England Journal of Medicine, 2008
- Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring studyBreast Cancer Research, 2007
- HER-2/neu Amplification Is an Independent Prognostic Factor in Gastric CancerDigestive Diseases and Sciences, 2006